Lessons From The Bone Therapeutics/Medsenic Merger With BioSenic's François Rieger, Ph.D.
Business Of Biotech
00:00
The Pros and Cons of the Acquisition
Dr. Rizier: Since three months, we don't stop from the morning to the night to work on the explanation of what we had done and what we want to do for the public. And it's now a volume, which is nearly 200 or 300 pages with a lot of verification, control, and everything. So that is something very, I didn't expect that, but this is very important for me right now. You see, with perspectives and with statements and what we are able really to do.
Transcript
Play full episode
